SAS Output

25-APR-2019 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9400 9383 0 0 0 0 0 02/28/2011 313 163
            9383 0 0 0 0 0      
 
    2 Y 2 Chemo and Endocrine Therapy 5000 2547 0 0 0 0 0 02/28/2011    
        3 Endocrine Therapy Alone   2536 0 0 0 0 0      
            5083 0 0 0 0 0      
 
  S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 1900 959 174 88 51 23 5 09/12/2013 428 198
        2 Blinded drug + Endocrine   963 172 92 46 23 6      
            1922 346 180 97 46 11      
 
  S1222-Brst,Fulv. +/- Ever. +/- Anastr. 1 T 1 Blinded treatment 840 12 0 0 0 0 0 05/15/2014 8 1
        2 Blinded treatment   12 0 0 0 0 0      
        3 Blinded treatment   13 0 0 0 0 0      
            37 0 0 0 0 0      
 
  S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 1 Y 1 Blinded Drug + Cisplatin 333 161 38 30 14 3 0 09/15/2016 256 114
        2 Blinded Drug + Cisplatin   164 43 25 16 4 1      
            325 81 55 30 7 1      
 
  S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1000 518 314 184 100 30 5 01/18/2017 475 206
            518 314 184 100 30 5      
 
    2 Y 2 Observation 1000 222 130 78 45 16 1 01/18/2017    
        3 MK-3475 (Pembrolizumab)   217 131 77 44 14 5      
            439 261 155 89 30 6      
 
  S1706-Breast, Inflammatory, RT +/- Olaparib 1 Y 1 Olaparib + RT 300 3 3 3 2 1 0 01/18/2019 129 58
        2 RT   2 2 2 2 0 0      
            5 5 5 4 1 0      
 
Yes A011106-Breast, Neoadj, ALTERNATE study 1 E Total Registrations   93 37 15 10 4 0 04/29/2014   112
            93 37 15 10 4 0      
 
  E1Z11-Brst,Genetic Predictors of AIMSS 1 E Total Registrations   156 6 0 0 0 0 08/13/2013   1
            156 6 0 0 0 0      
 
  NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo 1 E Total Registrations   72 21 8 3 2 1 10/16/2015   168
            72 21 8 3 2 1      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 E Total Registrations   7 7 3 1 0 0 06/22/2018 146 78
            7 7 3 1 0 0      
 
No A011401-Breast, adj, Stage II/III HER2-, weight loss 1 E Total Registrations   234 102 45 29 16 4 10/05/2016   246
            234 102 45 29 16 4      
 
    2 E Total Registrations   212 95 39 25 13 2 10/05/2016    
            212 95 39 25 13 2      
 
  A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 1 E Total Registrations   92 58 35 21 9 3 03/20/2017 356 205
            92 58 35 21 9 3      
 
  A221405-Breast, ET interruption, Pregnancy Outcomes 1 E Total Registrations   18 9 5 5 5 1 05/08/2017 127 51
            18 9 5 5 5 1      
 
  B51-Breast, Regional Nodal XRT 1 E Total Registrations   34 9 2 1 0 0 06/13/2014   159
            34 9 2 1 0 0      
 
  B55-Brst, Adj Olaparib for BRCA,TNBC 1 E Total Registrations   72 15 5 4 2 0 12/15/2014 440 184
            72 15 5 4 2 0      
 
    2 E Total Registrations   33 9 1 1 0 0 12/15/2014    
            33 9 1 1 0 0      
 
  EA1131-Brst, TNBC, Post-op Chemo vs Obs 0 E Total Registrations   28 10 8 4 1 1 11/12/2015   120
            28 10 8 4 1 1      
 
    1 E Total Registrations   16 7 5 2 0 0 11/12/2015    
            16 7 5 2 0 0      
 
  EA1151-Brst, Tomosynthesis Mammographic Screening 1 E Total Registrations   394 336 179 111 42 7 01/30/2018 148 71
            394 336 179 111 42 7      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 E Total Registrations   1 0 0 0 0 0 09/22/2017 329 143
            1 0 0 0 0 0